Centogene N.V. Common Shares - CNTG STOCK NEWS

CENTOGENE reported strong financial performance for FY 2020, with revenues more than doubling to €128.4 million. Q4 2020 saw a nearly quadrupling in revenues to €70.3 million, primarily driven by COVID-19 testing which contributed €59.8 million. The company achieved its highest annual adjusted EBITDA despite ongoing investments in rare disease initiatives. It added 100,000 patients to its database, indicating robust growth. The outlook for 2021 suggests a return to core business growth following new pharma partnerships and diagnostics recovery.

Centogene N.V. (Nasdaq: CNTG) has extended its partnership with Takeda Pharmaceutical Company Limited until March 2022 to provide genetic testing for patients with rare diseases. This collaboration enhances access to diagnostics globally, with Centogene's CEO, Andrin Oswald, emphasizing the commitment to improving patient outcomes. Centogene's proprietary platform incorporates data from over 595,000 patients, aiding in the identification and treatment of rare diseases. The partnership builds on Centogene's ongoing efforts to assist pharmaceutical companies in developing orphan drugs.

Centogene N.V. (Nasdaq: CNTG) will announce its financial results for the full year ended December 31, 2020, on April 15, 2021, and host a conference call at 8 a.m. EDT. The company focuses on rare diseases, utilizing a proprietary platform with over 3.6 billion weighted data points from approximately 595,000 patients. Centogene collaborates with over 40 pharmaceutical partners, enhancing the understanding and treatment of rare diseases. Investors can find details on the company’s Investor Relations page.

Centogene N.V. (Nasdaq: CNTG) has reached a significant milestone in its Rostock International Parkinson's Disease (ROPAD) Study by recruiting 10,000 participants, making it the largest genetic study on Parkinson's disease globally. With over 120 study sites worldwide, the focus is on understanding the role of genetics in Parkinson's progression, diagnosis, and treatment. The study includes a collaboration with Denali Therapeutics on targeted patient recruitment linked to LRRK2 mutations, potentially paving the way for new therapeutic options.

Centogene N.V. (Nasdaq: CNTG) announced positive voting results from its Extraordinary General Meeting, with shareholders approving key proposals. These include the appointments of Dr. Andrin Oswald and Dr. Jonathan Sheldon, along with the reappointment of Mr. Richard Stoffelen. The Company emphasizes its focus on advancing rare disease diagnosis and treatment through its extensive data platform, which houses over 3.6 billion data points from approximately 595,000 patients globally. The management expressed gratitude for shareholder support and aims to further enhance growth in the rare disease sector.

Centogene N.V. (Nasdaq: CNTG) reported a 212% revenue increase for Q3 2020 compared to Q3 2019, mainly due to expanding its COVID-19 testing services. The company raised its 2020 revenue guidance to over €100 million and signed 12 new pharmaceutical partnerships. Leadership transitioned with Dr. Andrin Oswald now as CEO, aimed at driving growth in rare diseases. Centogene's extensive testing infrastructure positions it among Europe's largest COVID testing agencies, enhancing its ability to invest in rare disease initiatives.

Centogene N.V. (Nasdaq: CNTG) will announce its financial results for Q3 2020 on December 16, 2020, at 8 a.m. EST, during a conference call. The company focuses on rare diseases, utilizing over 3.6 billion weighted data points from approximately 570,000 patients across 120 countries to improve treatment decisions and aid pharmaceutical partners in drug development. As of August 31, 2020, Centogene collaborates with over 40 pharmaceutical companies on 45 rare diseases, establishing a significant footprint in the global rare disease market.

Centogene and Alnylam Pharmaceuticals have launched a joint program named TRAMmoniTTR to conduct genetic screening for hereditary Transthyretin-related Amyloidosis (ATTRv). This initiative builds on the previous TRAM Study, which identified over 1% of 5,000 participants with ATTRv. The TRAMmoniTTR Study will monitor symptomatic and asymptomatic TTR-positive individuals for two years, using Centogene's biomarker profiling to enhance diagnostics. Experts from both companies emphasize the importance of early diagnosis and personalized treatment approaches.

Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics to enhance genetic testing for Aromatic L-amino Acid Decarboxylase (AADC) deficiency across Europe, the Middle East, and Latin America. This initiative will provide free biochemical and genetic testing to patients enrolled in the REVEAL CP study, aimed at identifying AADC deficiency in individuals with cerebral palsy. The study utilizes CentoCard® blood samples to detect elevated 3-O-Methyldopa levels, critical for timely diagnosis and treatment options for this ultra-rare genetic disorder.